Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the second quarter ended June 30, 2009.

"We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quarter, including continued acceleration of our important Quill(TM) SRS and HemoStream(TM) product lines," said Dr. William Hunter, President and CEO of Angiotech. "Despite the continued challenges we are experiencing in certain parts of our Base Medical Products business, the continued stabilization of our TAXUS(R)-derived royalty revenue, the possibility that Cook's Zilver(TM) paclitaxel-eluting peripheral stent may contribute additional royalty revenue and the recent FDA approval of our Option(TM) Inferior Vena Cava Filter leave us optimistic about the second half of 2009 and 2010."

    Second Quarter Financial Highlights

    -   Total revenue was $64.6 million.

    -   Net product sales were $47.2 million. Sales of our Proprietary
        Medical Products were $13.5 million, or 29% of total product sales.
        Sales of our Base Medical Products were $33.7 million, or 71% of
        total product sales.

    -   Royalty revenue was $17.0 million.

    -   Adjusted EBITDA (earnings before interest, taxes, depreciation and
        amortization, adjusted to exclude certain non-cash and non-recurring
        items) was $12.6 million.

    -   Research and development expenses were $6.8 million, and as adjusted
        to exclude non-cash stock-based compensation expenses and other non-
        recurring costs were $6.1 million.

    -   Selling, general and administrative expenses were $21.6 million, and
        as adjusted to exclude non-cash stock-based compensation expenses,
        certain litigation costs, non-recurring fi
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary ... at the specialized Wolvega Horse Clinic. , Due to ... was ruptured 90% and her deep digital flexor tendon ... sentence for a horse. , The clinic has performed ... This revolutionary regenerative option for ruptured tendons has ...
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... Md., Sept. 2 Micromet, Inc.,(Nasdaq: MITI ... novel, proprietary antibodies for the treatment of cancer,inflammation ... A. Phillips as Senior Vice President and Chief ... of the Company,s board of directors,since 2000, and ...
... a New Jersey-based,leading provider of prescription co-pay programs ... significantly expanded the scope of,the lawsuit that it ... the State,of New York, County of New York, ... of McKesson Corporation. PSKW is,now seeking, in addition ...
... The BEAUTIFUL study: a step further in title ... BEAUTIFUL study: efficacy of session title ivabradine in reduction of cardiovascular ... among patients with stable coronary ... dysfunction, ESC Hotline ...
Cached Biology Technology:Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 2With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients 3
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... have come up with a new twist in their efforts ... DNA genetic code. They have developed the first, versatile DNA ... key to unlocking the vital code behind human heredity and ... director of the Biodesign Institute,s Center for Single Molecule Biophysics, ...
... 2010) For years, doctors have warned patients to finish ... "superbug" that can mount a more powerful defense against the ... engineers indicates that treating bacteria with levels of antibiotics insufficient ... wide range of antibiotics. In the Feb. 12 issue ...
... help save the sight of patients with a type of ... University of Leeds found that the TSPAN12 gene is faulty ... Vitreoretinopathy), which affects the development of the eye. While ... of the same family may carry the faulty gene without ...
Cached Biology News:ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 2ASU scientists develop universal DNA reader to advance faster, cheaper sequencing efforts 3Low levels of antibiotics cause multidrug resistance in 'superbugs' 2Low levels of antibiotics cause multidrug resistance in 'superbugs' 3New gene discovery could help to prevent blindness 2
... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
Biology Products: